Intuitive Surgical stock holds steady as Asia expansion follows strong Q2 beat

Intuitive Surgical Inc. (US46120E6023) stock is trading in the mid-$390 range as of August 14, 2026, following a recent stretch in which the company reported double-digit revenue growth and expanded its global manufacturing footprint in Asia Pacific.

The latest quote snapshots as of August 14, 2026, show Intuitive Surgical shares around $394.51 on Nasdaq, reflecting a modest daily decline of 1.68% and placing the stock well below its 52-week high that previously reached above $600.

For investors, the combination of a strong second-quarter 2026 earnings beat and a new manufacturing facility in Malaysia is reinforcing the narrative that the business is still driven by rising procedure volumes and system placements even after a significant drawdown earlier in 2026.

Q2 2026 earnings delivered a clear beat

Per a recent earnings coverage dated August 17, 2026, Intuitive Surgical reported that second-quarter 2026 revenue increased 18.4% year over year to $2.89 billion, underscoring solid demand across its robotic-assisted surgery portfolio. The Q2 2026 earnings article noted that this revenue growth outpaced the prior-year period and represented a stronger operational performance than the market had expected.

The same Q2 2026 report highlighted that adjusted earnings per share reached $2.80, clearly above the consensus analyst estimate of $2.48 for the quarter, resulting in an EPS beat of $0.32 per share and signaling operating leverage as procedure volumes scale.

Combined da Vinci and Ion procedures grew 16% year over year in Q2 2026, while Intuitive placed 468 da Vinci systems and 55 Ion systems in the quarter, indicating that hospitals and surgical centers are still investing in the company’s platforms despite the share price volatility earlier in 2026. A corporate-news summary emphasized that these placements support recurring instrument and service revenue over time.

Intuitive’s guidance commentary referenced global da Vinci procedure growth expectations in a band of 13.5% to 15.5% for full-year 2026, keeping procedure expansion at the center of the long-term investment case and framing Q2’s 16% growth as slightly above the midpoint of the outlook range.

From a margin perspective, the strong Q2 2026 beat on both revenue and adjusted EPS suggests that scale effects from higher procedure volumes and system placements are helping to offset cost pressures from investment in new technologies and geographic expansion.

Analyst consensus and stock performance in 2026

The stock’s mid-$390 price level as of August 14, 2026, compares with an average analyst price target of $508.68, implying upside potential in excess of $110 per share from recent trading levels according to a consensus compiled in mid-August 2026. A recent institutional filing overview cited a consensus rating categorized as Moderate Buy, supported by a majority of buy recommendations and a smaller cohort of hold and sell ratings.

One analyst overview dated August 16, 2026, pointed to a Street-high target of $685 and a consensus target around $480.93, implying a near-20% upside from current levels and considerably more upside at the highest target, although that broader analyst context included multiple rating tiers from strong buy to strong sell. An analyst-upgrade news story observed that a recent rating change to an outperform stance came alongside a $500 price objective.

A separate commentary dated August 17, 2026, remarked that Intuitive Surgical shares have declined 33% so far in calendar 2026 despite averaging annual gains of 17% over the past decade, underscoring how the current year’s drawdown contrasts with the longer-term performance profile for the stock. This 2026 performance article framed the year-to-date loss against the company’s historical capacity to compound shareholder returns.

Recent institutional activity has included new stakes and position increases, with one August 17, 2026, filing summary noting that a European investment firm added more than 5,000 shares in Q2 2026, valued at around $2.04 million at the time of purchase, and insider transaction data over the last 90 days showing that company executives sold 17,106 shares for total proceeds near $6.95 million.

For many market participants, the juxtaposition of a 33% year-to-date decline in 2026 with double-digit revenue growth and an EPS beat in Q2 2026 presents a debate about whether the current valuation reflects near-term risk, longer-term opportunity, or a combination of both.

Asia Pacific manufacturing expansion in Malaysia

On August 17, 2026, Intuitive announced that it had entered into a lease agreement with Penang Development Corporation for a new manufacturing facility in Bandar Cassia Technology Park in Penang, Malaysia, marking a strategic expansion of its Asian production footprint. The Penang facility announcement explained that the site will produce surgical instruments and electromechanical devices used with the da Vinci surgical system.

The new facility is intended to support growing demand for Intuitive’s technologies across the Asia Pacific region, where da Vinci surgical systems have enabled surgeons to treat more than 2.5 million patients across 13 markets over more than two decades, according to the same release dated August 17, 2026.

Intuitive’s decision to expand manufacturing in Malaysia diversifies its production base and places more capacity closer to growth markets, which could lower lead times, reduce logistics costs, and improve responsiveness to demand spikes for instruments and accessories tied to the installed base of da Vinci systems in Asia Pacific.

For investors, the Penang move ties directly into the company’s long-term growth thesis: as procedure volumes rise, demand for instruments and service contracts attached to the systems also increases, and regional manufacturing can protect margins while scaling to meet that demand.

The manufacturing expansion also suggests confidence in the sustainability of the region’s growth trajectory, complementing the global guidance for da Vinci procedure growth in the 13.5% to 15.5% range for 2026.

Market data and trading context

Market data snapshots compiled on August 14, 2026, show Intuitive Surgical shares closing at $395.00 on Nasdaq, with an indicated prior close at $394.51 and an intraday change of 0.12%, based on a quote page that outlined these levels for the regular 4:00 p.m. ET session. A recent quote overview listed the current price of Intuitive Surgical at $394.51 in U.S. dollars.

Another stock overview as of August 14, 2026, reiterated the $394.51 close and indicated a daily decline of 1.68%, highlighting that the shares remain some distance below prior highs after their 2026 drawdown. An equity analysis page captured this quote alongside market-capitalization data and trading-volume context.

An earlier corporate-news item on August 17, 2026, referenced a market value of $139.37 billion at the time of the $394.51 quote and noted a 52-week range from a low around $414.30 to a high of $603.88, offering a numerical frame for where the current price sits in that one-year band. The same corporate-news report emphasized that the recent price level is well below the peak of the range.

A live news dashboard as of August 17, 2026, listed Intuitive Surgical at $392.06 at 10:06 a.m. Eastern time, representing a small intraday loss of 0.62%, underscoring day-to-day volatility around the mid-$390 mark while broader valuation narratives hinge on longer-term earnings and growth projections. This news overview described the quoted value as a fair market value price.

Given the 2026 year-to-date decline of 33% highlighted in the performance commentary, the current mid-$390 price is notable because it reflects both the compression from prior highs and the market’s ongoing willingness to assign a large-cap valuation to a company that continues to beat earnings expectations and expand its manufacturing footprint.

Intuitive manufacturing and the da Vinci system

The da Vinci surgical system remains Intuitive Surgical’s flagship product line, forming the backbone of its robotic-assisted surgery offerings and driving recurring revenue through instruments, accessories, and service contracts. In Q2 2026, the company placed 468 da Vinci systems worldwide, which supports the installed base that generates follow-on revenue as surgeons conduct procedures and hospitals perform routine maintenance.

The system allows surgeons to perform minimally invasive procedures across multiple specialties, and the Ion platform complements da Vinci with capabilities in pulmonology and lung biopsy navigation, giving Intuitive a broader footprint in diagnostic and therapeutic interventions.

The new manufacturing facility in Penang, Malaysia, will produce surgical instruments and electromechanical devices used with the da Vinci system, which suggests that Intuitive is aligning its production capacity with geographic demand patterns, especially in Asia Pacific markets where surgeon adoption and patient volumes are rising.

Over more than two decades, Intuitive’s systems have enabled over 2.5 million patients to be treated in Asia Pacific, highlighting the depth of the company’s engagement in the region and the need for a robust supply chain for instruments and system components.

With da Vinci system placements and procedure volumes rising, manufacturing and logistics efficiency becomes increasingly important for protecting margins and ensuring that hospitals can access the instruments they need without delays, particularly if demand accelerates beyond current guidance ranges.

Closing view on Intuitive Surgical stock

As of the close on August 14, 2026, Intuitive Surgical stock traded at $395.00 on Nasdaq in U.S. dollars, backed by a market capitalization of roughly $139.37 billion at a recent $394.51 quote and a 52-week range that extends up to $603.88, illustrating the distance between current pricing and prior peaks.

For investors assessing the shares, the key numerical anchors include Q2 2026 revenue of $2.89 billion, up 18.4% year over year, adjusted EPS of $2.80 versus a consensus of $2.48, procedure growth of 16% year over year, and full-year 2026 da Vinci procedure growth guidance of 13.5% to 15.5%, alongside the strategic expansion of manufacturing capacity in Malaysia to serve rising demand in Asia Pacific.

Fact box

Company: Intuitive Surgical Inc.

ISIN: US46120E6023

Ticker: ISRG

Exchange: Nasdaq

Price (as of August 14, 2026, 4:00 p.m. ET): $395.00 USD

Market cap: $139.37 billion (as of August 14, 2026)

Sector / Industry: Health care / Medical devices

Index membership: S&P 500